A retrospective study of interrupted BRAFi (Vemurafenib and Dabrafenib) versus concomitant radiotherapy in melanoma patients

Trial Profile

A retrospective study of interrupted BRAFi (Vemurafenib and Dabrafenib) versus concomitant radiotherapy in melanoma patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Dabrafenib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2018 New trial record
    • 13 Feb 2018 Results assessing efficacy and safety of BRAFi interrupted versus concomitant therapy during radiotherapy published in the British Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top